FCMI
RCUS icon

Foresite Capital Management IV’s Arcus Biosciences RCUS Stock Holding History

Foresite Capital Management IV’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-295,000
Closed -$4.11M – 22
2018
Q3 		$4.11M Hold
295,000
– – 1.35% 16
2018
Q2 		$3.61M Sell
295,000
-355,000
-55% -$5.57M 1.23% 14
2018
Q1 		$10M Buy
+650,000
New +$10.8M 4.16% 9

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresite Capital Management IV's RCUS Position: Q4 2018 in Review

Foresite Capital Management IV sold out of Arcus Biosciences (RCUS) in Q4 2018, closing a stake of 295,000 shares — an estimated $4.11M sold.

Foresite Capital Management IV first reported a position in RCUS in Q1 2018 and held it in 3 quarters. The position peaked at $10M in Q1 2018. 67 funds tracked by Wall St. Rank hold RCUS as of Q4 2018.

  • Foresite Capital Management IV reported no remaining Arcus Biosciences position as of Q4 2018 after selling out during the quarter.
  • Foresite Capital Management IV sold 295,000 Arcus Biosciences shares in Q4 2018, an estimated $4.11M.
  • Foresite Capital Management IV first reported a position in Arcus Biosciences in Q1 2018 and held it in 3 quarters.
  • Foresite Capital Management IV's Arcus Biosciences position peaked at $10M in Q1 2018.
  • 67 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2018.

Based on Foresite Capital Management IV's 13F filing for Q4 2018, filed 13 Feb 2019.